Apr 20, 2020
Category: Pipac
Posted by: pipac

Due to COVID-19, we are canceling the workshop on 4-5 June 2020.

Mar 17, 2020
Category: Pipac
Posted by: pipac

Workshop, Odense University Hospital, June 4-5, 2020:

Due to the COVID-19 situation there is a significant risk of cancellation of the Workshop. Final decision will be made no later than April 15th, 2020.

We will keep you informed through our website and

Mar 13, 2020
Category: Pipac
Posted by: pipac

Due to the Corona virus, we are aware that it may affect our ability to hold our PIPAC workshop on June 4-5, 2020. We are closely following developments and will update the website for any changes.

Dec 17, 2019
Category: Pipac
Posted by: pipac

Fourth Scandinavian PIPAC workshop - June 4-5, 2020




PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) treatment of peritoneal carcinomatosis

Peritoneal carcinomatosis (PC) represents end stage disease in many types of cancer, and the majority of patients with PC will die from their disease within six months. Platinum-based systemic chemotherapy may prolong survival in selected patients, but poor performance status, low response rates, and treatment toxicity have led to conservative (nihilistic) treatment strategies in these patients. However, patients with PC who are in good condition and with a remaining life expectancy of more than a few months, may still have an unmet need for additional treatment in order to be able to perform with a high quality of life for as long as possible. These patients have often tried several lines of systemic chemotherapy (SC) with disappointing results, and alternative and more effective treatment strategies are desperately needed.

PIPAC is a minimal invasive administration of aerosolized chemotherapy within the abdominal cavity, where the laws of physics allow a high tissue concentration of chemotherapy, but without the usual side effects and toxicity of SC. Preliminary clinical data suggest a significant efficacy of PIPAC in platinum-resistant PC, with a confirmed low adverse events profile and with no occupational health safety problems.

This could indicate treatment progress in a difficult palliative situation, but perhaps PIPAC may also challenge the present treatment strategies in cancer patients who have not reached end stage disease, yet.

Odense PIPAC Center (OPC) is the first Scandinavian cancer center to perform the PIPAC procedures, and the first patient was treated on October 29th, 2015. Since then, OPC has performed more than 220 PIPAC procedures in protocolled prospective trials (see TRIALS), and we have confirmed the high safety profile of PIPAC as well as the positive effect on several patient outcome parameters.

More information on PIPAC is available at this homepage. We encourage both patients and health care personnel to use these resources and to contact us if additional information is needed.


If you need to contact Odense PIPAC Center, please feel free to contact us at this email: